N. Mohamed

发表

Carfilzomib and dexamethasone vs bortezomib and dexamethasone in patients with relapsed multiple myeloma: results of the phase 3 study ENDEAVOR (NCT01568866) according to age subgroup

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2017, Leukemia & lymphoma.

Evaluation of antigen-based heteropolymer for treatment of systemic lupus erythematosus in a nonhuman primate model.

Juan Li, S. Pincus, R. Zabinski, 2002, Clinical immunology.

Development and Validation of a Stability-Indicating Chromatographic Method for the Determination of Indacaterol Maleate with Glycopyrronium Bromide in Mixture

M. Fouad, S. T. Hassib, N. Mohamed, 2019, Current Pharmaceutical Analysis.

Serial Echocardiographic Assessment of Patients (Pts) with Relapsed Multiple Myeloma (RMM) Receiving Carfilzomib and Dexamethasone (Kd) Vs Bortezomib and Dexamethasone (Vd): A Substudy of the Phase 3 Endeavor Trial (NCT01568866)

S. Russell, H. Goldschmidt, M. Dimopoulos, 2015 .

A Phase III, randomized, open-label study (CONTACT-02) of cabozantinib plus atezolizumab versus second novel hormone therapy in patients with metastatic castration-resistant prostate cancer.

J. Carles, N. Agarwal, B. McGregor, 2022, Future oncology.

A DeImmunized chimeric anti-C3b/iC3b monoclonal antibody enhances rituximab-mediated killing in NHL and CLL cells via complement activation

K. Takeshita, G. Inghirami, Xin Zhang, 2005, Cancer Immunology, Immunotherapy.

Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2016, Leukemia.

Identification of new potent phthalazine derivatives with VEGFR-2 and EGFR kinase inhibitory activity.

K. Amin, F. Awadallah, N. Mohamed, 2016, European journal of medicinal chemistry.

A High-Affinity Monoclonal Antibody to Anthrax Protective Antigen Passively Protects Rabbits before and after Aerosolized Bacillus anthracis Spore Challenge

Michael Babin, Juan Li, S. Pincus, 2005, Infection and Immunity.

Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study.

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2016, The Lancet. Oncology.

Enhancement of Anthrax Lethal Toxin Cytotoxicity: a Subset of Monoclonal Antibodies against Protective Antigen Increases Lethal Toxin-Mediated Killing of Murine Macrophages

A. Friedlander, Juan Li, Arthur M. Friedlander, 2004, Infection and Immunity.

Correlation of Target Molecule Expression and Overall Response in Refractory Cutaneous T-Cell Lymphoma Patients Dosed with Mogamulizumab (KW-0761), a Monoclonal Antibody Directed Against CC Chemokine Receptor Type 4 (CCR4)

M. Goswami, J. Jorgensen, M. Duvic, 2012 .

Carfilzomib–dexamethasone vs bortezomib–dexamethasone in relapsed or refractory multiple myeloma by cytogenetic risk in the phase 3 study ENDEAVOR

H. Goldschmidt, M. Dimopoulos, A. Palumbo, 2016, Leukemia.

A phase 3 study (COSMIC-313) of cabozantinib in combination with nivolumab and ipilimumab in patients with previously untreated advanced renal cell carcinoma of intermediate or poor risk

T. Powles, R. Motzer, T. Choueiri, 2020 .